Price data is not available
Akari Therapeutics PLC
AKTXNASDAQ
Akari Therapeutics (AKTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | FY '23 | FY '22 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||||
| Estimate | $-1.04 | $-2.80 | $-2.80 | $-4.40 | — | — |
| Actual | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Surprise | +100.0% | +100.0% | +100.0% | +100.0% | — | — |
| Revenue | ||||||
| Estimate | — | — | — | — | — | — |
| Actual | — | $0 | $0 | $0 | $0 | $0 |
| Surprise | — | — | — | — | — | — |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-2.38 | $-2.11 |
| Revenue | ||
| Consensus | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $0 | $-1.04 | 100.0 % |
| Q1 | May 19, 2026 | $0 | $-2.80 | 100.0 % |
| Q4 | Mar 30, 2026 | $0 | $-2.80 | 100.0 % |
| Q3 | Nov 13, 2025 | $0 | $-4.40 | 100.0 % |
